Introduction: Androgenetic alopecia (AGA), is a common form of hair loss affecting people worldwide due to androgenetic miniaturization of hair follicles. It is characterized by a progressive thinning of the hair, primarily on the scalp. While various treatments are available, there is a growing interest in the use of injectable Growth Factor Concentrate (GFC). GFC is a modification of PRP that is obtained from the patient's own blood and contains high concentrations of growth factors, which are believed to promote hair growth and prevent hair loss. The primary objective of this dissertation is to evaluate the efficacy and safety of injectable GFC in the treatment of androgenetic alopecia. This dissertation will employ a prospective, interventional study design. Methodology: A total of 45 patients diagnosed with androgenetic alopecia will be recruited. The treatment group will receive three sessions of I-GFC injections at 1 month, 2 month and 3 months with a follow-up period of 6 months. Hair growth was assessed through standardized photographic documentation and Phototrichogram at 1-, 2-, 3-, and 6-months post-treatment, along with patient satisfaction evaluation using validated questionnaires at the 6-month follow-up. Results: Shapiro wilkinson test for normality reported a significant difference (P<0.05), Hence Non-Parametric tests are used for the analysis. Regarding ‘Anagen Phase’, ‘Hair density’ and ‘Hair growth’, within group analysis was done by Friedman test and reported significant difference (P<0.05) between 1 month & 3 months. Nonetheless, the minor decline in hair density and follicle activity during the 6-month follow-up prompts additional exploration to grasp the factors behind this pattern. Patient satisfaction with treatment outcomes revealed high levels of satisfaction with the appearance of the front (80%), top (70%), and overall scalp regions (85%) after the treatment. Conclusion: The efficacy of I-GFC in managing androgenetic alopecia was enhanced, proving to be a safe, simple, time-efficient, and cost-effective adjuvant treatmen.